AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.
The aim of the research by the Medical University of Vienna was to create physiological-relevant in vitro tissue models that offer better predictability and the potential to improve drug screening outcomes in pre-clinical studies. Despite the advances of spheroid models in pharmaceutical screening applications, variations in spheroid size and consequential altered cell responses traditionally have led to…
London, UK, 27 October 2021 – Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited (“Takeda”) for a pre-negotiated upfront payment, as well as potential development and regulatory milestones. GammaDelta Therapeutics is a UK-headquartered company founded upon world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute and supported by Cancer Research Technology. GammaDelta is focused on…
Dr Marcin Mankowski, Co-founder and Deputy Managing Partner of tranScrip, has been appointed tranScrip’s new Managing Partner.
Marcin has been integral to the success of the business over the last decade and is transitioning to the role at an exciting stage of the company’s growth. Underpinned by a recent significant minority investment from Palatine Private Equity Impact Fund, tranScrip is set to rapidly drive revenues with both organic growth and strategic acquisitions.
Marcin is a highly respected pharmaceutical physician with more than 25 years of big pharma, biotech and service sector…
22nd October 2021 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full service finance company for the life sciences, pharma, biotech, deep tech and new energy sector, has recently expanded its portfolio of book-keeping, tax, and CFO services into the UK market. With the appointment of Charles Richmond as their new Director Accounting UK, the company takes the next step towards becoming a dominant player within the international market. In this new position, Charles Richmond is responsible for continued growth of the overall high-quality portfolio. His mission includes giving further…
Click here to view the October 2021 edition of Dates for Your Diary
TOKYO and NOTTINGHAM, UK |21 October 2021 - Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc, and We are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, today announce a new collaborative sponsorship and first of its kind initiative to support early stage science ventures. The “Future Innovator Prize” offers scientists and biotech start-ups one year of free accommodation at selected We are Pioneer Group locations and membership to the WAPG’s community of scientists, technologists and…
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.
Under the terms of the agreement, F-star will grant…
Cambridge, UK, 20 October 2021: Mursla, a liquid biopsy company, is delighted to announce that it has been granted patent GB 2583550B for its novel nanoelectronics-based sensitive detection method for exosomes.
Exosomes, usually 50-150 nm in diameter, are heterogenous vesicles (diverse bubbles) naturally secreted by cells during their lives. Exosomes have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (proteins, lipids, nucleic acids and metabolites) either locally or to distant sites via the circulatory system. Their content…
Leading biotech product development consultancy Boyds has added two experienced product development experts to its team, amid growing demand for specialist Product Development services from clients in the UK, Europe and the US.
Diane Shattock Ph.D., joins as Director of Product Development and Ian Hollingsworth M.Sc., as Associate Director of Product Development. Both are working alongside Boyds’ Vice President of Product Development, Nick Meyers Ph.D.
The hires are central to Boyds’ planned expansion of the Product Development team and its clear strategy of expansion into the US,…
The UK’s Patents Court has recently handed down judgment in Royalty Pharma Collection Trust v Boehringer Ingelheim GmbH . This author will not get into the detail since the case concerned German law – but it is clear that interesting points on patent licensing and substantive patent law feature extensively.
Royalty Pharma sued Boehringer for about €23 million in outstanding royalties on linagliptin containing products for diabetes treatment. The claim arises from an amended agreement negotiated in 2015. Boehringer counterclaimed for an unquantified overpayment relating to the original…